- Home
- NUVB vs REAL Comparison
NUVB vs REAL Comparison
Compare NUVB & REAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- REAL
- Stock Information
- Founded
- NUVB 2018
- REAL 2011
- Country
- NUVB United States
- REAL United States
- Employees
- NUVB N/A
- REAL N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- REAL Other Specialty Stores
- Sector
- NUVB Health Care
- REAL Consumer Discretionary
- Exchange
- NUVB Nasdaq
- REAL Nasdaq
- Market Cap
- NUVB 837.0M
- REAL 871.2M
- IPO Year
- NUVB N/A
- REAL 2019
- Fundamental
- Price
- NUVB $3.89
- REAL $8.67
- Analyst Decision
- NUVB Strong Buy
- REAL Buy
- Analyst Count
- NUVB 6
- REAL 4
- Target Price
- NUVB $8.00
- REAL $11.13
- AVG Volume (30 Days)
- NUVB 6.2M
- REAL 4.7M
- Earning Date
- NUVB 11-05-2025
- REAL 11-03-2025
- Dividend Yield
- NUVB N/A
- REAL N/A
- EPS Growth
- NUVB N/A
- REAL N/A
- EPS
- NUVB N/A
- REAL N/A
- Revenue
- NUVB $14,355,000.00
- REAL $636,971,000.00
- Revenue This Year
- NUVB $332.80
- REAL $14.27
- Revenue Next Year
- NUVB $360.12
- REAL $9.94
- P/E Ratio
- NUVB N/A
- REAL N/A
- Revenue Growth
- NUVB 900.35
- REAL 12.68
- 52 Week Low
- NUVB $1.54
- REAL $2.24
- 52 Week High
- NUVB $4.09
- REAL $11.38
- Technical
- Relative Strength Index (RSI)
- NUVB 83.37
- REAL 71.33
- Support Level
- NUVB $2.87
- REAL $7.30
- Resistance Level
- NUVB $3.08
- REAL $8.00
- Average True Range (ATR)
- NUVB 0.22
- REAL 0.41
- MACD
- NUVB 0.08
- REAL 0.04
- Stochastic Oscillator
- NUVB 86.52
- REAL 88.67
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.